Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice
Open accessThe DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Abstract
The tumor necrosis factor type 1 death receptor (TNFR1) contributes to apoptosis. TNFR1, a subgroup of the TNFR superfamily, contains a cytoplasmic death domain. We recently demonstrated that the TNFR1 cascade is required for amyloid β protein (Aβ)–induced neuronal death. However, the function of TNFR1 in Aβ plaque pathology and amyloid precursor protein (APP) processing in Alzheimer's disease (AD) remains unclear. We report that the deletion of the TNFR1 gene in APP23 transgenic mice (APP23/TNFR1−/−) inhibits Aβ generation and diminishes Aβ plaque formation in the brain. Genetic deletion of TNFR1 leads to reduced β-secretase 1 (BACE1) levels and activity. TNFR1 regulates BACE1 promoter activity via the nuclear factor-κB pathway, and the deletion of TNFR1 in APP23 transgenic mice prevents learning and memory deficits. These findings suggest that TNFR1 not only contributes to neurodegeneration but also that it is involved in APP processing and Aβ plaque formation. Thus, TNFR1 is a novel therapeutic target for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several lines of evidence had linked the inhibition of TNF-α signaling with reduction of both Aβ and tau pathologies in vivo36,37.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“The receptorinduced multimerization of a Fas-associated death domain protein leads to caspase activation, which causes degradation of specifi c target proteins, ultimately damaging cell integrity (Ashkenazi and Dixit, 1998).”
BackgroundVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation
Hsu, H., Xiong, J., & Goeddel, D. V. (1995) · Cell · doi:10.1016/0092-8674(95)90070-5 · Cited by 2,012
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Skalli, O., Ropraz, P., Trzeciak, A., Benzonana, G., Gillessen, D., & Gabbiani, G. (1986) · The Journal of cell biology · doi:10.1083/jcb.103.6.2787 · Cited by 1,621
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · cited 1×
“This might be because the APP transgene is controlled by different promoters in APP23 and Tg2576 mice (Irizarry et al., 1997; Sturchler-Pierrat et al., 1997).”
BackgroundSelf-citationFarris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Research works printed but not linked: 2
- 2003, Science., 299, 1014
- 2005, Med. Sci. Monit., 11, BR357
Cited by
Items 201–300 of 390
Ren, S., Breuillaud, L., Yao, W., Yin, T., Norris, K. A., Zehntner, S. P., & D’Adamio, L. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016395 · Cited by 47
IKKβ Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology
Liu, Y., Liu, X., Hao, W., Decker, Y., Schomburg, R., Fülöp, L., Pasparakis, M., Menger, M. D., & Fassbender, K. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1348-14.2014 · Cited by 46
Lisak, R. P., Nedelkoska, L., Studzinski, D. M., Bealmear, B., Xu, W., & Benjamins, J. A. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.06.010 · Cited by 47
Kim, N., Do, J., Ju, I. G., Jeon, S. H., Lee, J. K., & Oh, M. S. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00792-7 · Cited by 46
Amyloidosis in Retinal Neurodegenerative Diseases
Masuzzo, A., Dinet, V., Cavanagh, C., Mascarelli, F., & Krantic, S. M. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00127 · Cited by 51
Yang, S., Pascual-Guiral, S., Ponce, R., Giménez-Llort, L., Baltrons, M. A., Arancio, O., Palacio, J. R., Clos, V. M., Yuste, V. J., & Bayascas, J. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00435 · Cited by 44
Kumar, A., Ekavali, Mishra, J., Chopra, K., & Dhull, D. K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4095-7 · Cited by 45
“TNF-α, a pro-inflammatory cytokine, has been proposed to be involved in the pathogenesis of AD (He et al. 2007; Yamamoto et al. 2007; Tobinick and Gross 2008).”
BackgroundYu, X., Guan, P.-P., Zhu, D., Liang, Y.-Y., Wang, T., Wang, Z., & Wang, P. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00172 · Cited by 49
Effects of (−)Epicatechin on the Pathology of APP/PS1 Transgenic Mice
Yue-Qin, Z., Wang, Y., & Zhou, X. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00069 · Cited by 47
Hampel, H. J., Lista, S., Vanmechelen, E., Zetterberg, H., Giorgi, F. S., Galgani, A., Blennow, K., Caraci, F., Das, B., Yan, R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00686-3 · Cited by 46
Naudé, P. J. W., Dobos, N., van der Meer, D., Mulder, C. K., Pawironadi, K. G. D., den Boer, J. A., van der Zee, E. A., Luiten, P. G. M., & Eisel, U. L. M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.10.006 · Cited by 44
Wang, J., Lei, X., Cheng, X., Zhang, X., Liu, G., Cheng, J., Xu, Y., Ju, Z., Zhou, W., & Zhang, Y. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0226-6 · Cited by 42
Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Wang, H., Shen, Y., Chuang, H., Chiu, C., Ye, Y., & Zhao, L. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190503151648 · Cited by 41
Self-citationInflammation in Neurodegenerative Disorders: Friend or Foe?
Galimberti, D., Fenoglio, C., & Scarpini, E. (2008) · Current Aging Sciencee · doi:10.2174/1874609810801010030 · Cited by 41
Microglia-derived TNF-α mediates Müller cell activation by activating the TNFR1-NF-κB pathway
Ji, M., Sun, Q., Zhang, G., Huang, Z., Zhang, Y., Shen, Q., & Guan, H. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108852 · Cited by 41
Carriba, P., Jiménez, S., Navarro, V., Moreno‐González, I., Barneda‐Zahonero, B., Moubarak, R. S., López‐Soriano, J., Gutiérrez, A., Vitórica, J., & Comella, J. X. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.6 · Cited by 45
Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy
Cheng, X., He, P., Yao, H., Dong, Q., Li, R., & Shen, Y. (2014) · Neurology · doi:10.1212/wnl.0000000000000403 · Cited by 38
Self-citationmiRNAs Identify Shared Pathways in Alzheimer’s and Parkinson’s Diseases
Sadlon, A., Takousis, P., Alexopoulos, P., Εvangelou, Ε., Prokopenko, I., & Perneczky, R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.006 · Cited by 41
Singh, A., Jones, O. D., Mockett, B. G., Ohline, S. M., & Abraham, W. C. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1492-19.2019 · Cited by 42
“Nonetheless, given the potential involvement of TNF in AD as suggested by preclinical experiments (He et al., 2007; McAlpine et al., 2009), it is worth exploring the optimal dosage and route of administration of TNF antagonists/inhibitors in the treatment of this currently incurable disease (Clark…”
BackgroundGao, X., Li, S., Cong, C., Wang, Y., & Xu, L. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2302680 · Cited by 50
“Both TNF and its type 1 receptor (TNFRI) are involved in AD-associated cerebral neuroinflammation and regulate amyloid formation through secreted enzymes [70].”
BackgroundSun, Q., Hampel, H. J., Blennow, K., Lista, S., Levey, A. I., Tang, B., Li, R., & Shen, Y. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140177 · Cited by 47
Self-citationShokouhi, G., Kosari‐Nasab, M., & Salari, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118049 · Cited by 37
Potential Immunotargets for Alzheimer's Disease Treatment Strategies
Fernández, P. L., Britton, G. B., & Rao, K. S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121222 · Cited by 37
“Deletion of TNF- death receptor in an AD mice model inhibits A generation and plaque formation and also prevents learning and memory deficits, confirming a deleterious role of TNF- in AD pathogenesis [131].”
BackgroundHe, P., Staufenbiel, M., Li, R., & Shen, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu370 · Cited by 33
Self-citationJiang, H. X., He, P., Xie, J., Staufenbiel, M., Li, R., & Shen, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu206 · Cited by 40
Self-citationMicroglia and modifiable life factors: Potential contributions to cognitive resilience in aging
Duggan, M. R., & Parikh, V. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113207 · Cited by 41
Gebril, H. M., Aryasomayajula, A., de Lima, M. R. N., Uhrich, K. E., & Moghe, P. V. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00393-7 · Cited by 40
“In AD, microglial activation and the subsequent release of pro-inflammatory cytokines lead to neuronal damage and loss of neuronal circuits [19, 74].”
BackgroundFecal Microbiota Transplantation Improves Cognitive Function of a Mouse Model of Alzheimer's Disease
Jiang, X., Zheng, Y., Sun, H., Dang, Y., Yin, M., Xiao, M., & Wu, T. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70259 · Cited by 39
Kamal, M. A., Priyamvada, S., Anbazhagan, A. N., Jabir, N. R., Tabrez, S. S. M., & Greig, N. H. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660137 · Cited by 39
“These studies, together with others reporting that (i) TNF-α polymorphisms that increase TNF-α production may elevate AD risk, particularly in patients carrying one or more apolipoprotein E ε4 alleles [92–94] and that (ii) genetic ablation of TNF-α receptor 1 (TNFR1) in APP23 AD mice [95] or a selective lowering of se…”
ResultMa, Y., Ma, B., Shang, Y., Yin, Q., Yan, H., Xu, S., Shen, C., Hou, X., & Liu, X. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.001 · Cited by 35
“There is evidence suggesting that the genetic inactivation of TNF receptor-mediated NF-κB signal transduction resulted in reduction of Aβ levels in AD mice (He et al., 2007).”
Kumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 42
Zhang, H., Sachdev, P. S., Wen, W., Crawford, J. D., Brodaty, H., Baune, B. T., Kochan, N. A., Slavin, M. J., Reppermund, S., Kang, K., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.008 · Cited by 32
Ali, M., Saleem, U., Anwar, F., Imran, M., Nadeem, H., Ahmad, B., Ali, T., Atta-ur-Rehman, & Ismail, T. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03229-w · Cited by 33
Anti-Inflammatory Drugs in Psychiatry
Berthold-Losleben, M., Heitmann, S., & Himmerich, H. (2009) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152809789352221 · Cited by 32
omairi, N. E. A., Albrakati, A., Kassab, R. B., Lokman, M. S., Elmahallawy, E. K., Amin, H. K., & Moneim, A. E. A. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00407-2 · Cited by 33
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors
Przybyłowska, M., Dzierzbicka, K., Kowalski, S., Chmielewska, K., & Inkielewicz‐Stępniak, I. (2020) · Current Neuropharmacology · doi:10.2174/1570159x19666201218103434 · Cited by 34
“Mice lacking TNFR1 (TNF-α receptor) crossed with the transgenic AD model exhibit mitigated hippocampal microglial activation, reduced plaque deposition and improved performance of incognitive tasks [60].”
BackgroundEfficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice
Ou, W., Ohno, Y., Yang, J., Chandrashekar, D. V., Abdullah, T., Sun, J., Murphy, R., Roules, G. C., Jagadeesan, N., Cribbs, D. H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102200 · Cited by 32
Zhang, K., Li, Y.-J., Feng, D., Zhang, P., Wang, Y., Li, X., Liu, S., Wu, Y., & Zhao, M. (2017) · Scientific Reports · doi:10.1038/srep43594 · Cited by 39
Xiao, J., Yao, R., Xu, B., Wen, H., Zhong, J., Li, D., Zhou, Z., Xu, J., & Wang, H. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00745-w · Cited by 30
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 34
Hao, W., Luo, Q., Tomic, I., Quan, W., Hartmann, T., Menger, M. D., Fassbender, K. C., & Liu, Y. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2363014 · Cited by 30
Wątroba, M., & Szukiewicz, D. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.962769 · Cited by 33
“Therefore, further research studies are needed to verify overall effect of SIRT2 and its inhibitors towards neuroinflammation in the course of AD, although inhibitors of TNF-α dependent signaling usually improve the cognitive performance of AD patients (He et al., 2007).”
BackgroundThe involvement of microglia in Alzheimer's disease: a new dog in the fight
Moore, Z., Taylor, J. M., & Crack, P. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14546 · Cited by 29
Fang, W., Liao, W., Zheng, Y., Huang, X., Weng, X., Fan, S., Chen, X., Zhang, X., Chen, J., Xiao, S., et al. (2019) · Europe PMC (PubMed Central) · Cited by 37
Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 32
“In animal models of Alzheimer’s disease, selective ablation of microglia, the primary source of proinflammatory cytokines in the CNS, or inhibition of TNF signalling, significantly reduces Ab deposition while rescuing cognitive defects (He et al., 2007; Shi et al., 2011; Sosna et al., 2018).”
BackgroundCastro, M. A. D., & Volterra, A. (2021) · Glia · doi:10.1002/glia.24128 · Cited by 32
“ory deficits (He et al., 2007), although a specific role for the astrocyte TNFR1 receptor has not been identified yet.”
BackgroundCytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimers Disease
Nagae, T., Araki, K., Shimoda, Y., Sue, L. I., Beach, T. G., & Konishi, Y. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000441 · Cited by 30
“Inhibiting TNFα signaling reduced Aβ generation and plaque formation, and it prevented learning and memory deficits in APP23 transgenic mice [150].”
BackgroundCognitive resilience in Alzheimer’s disease: Mechanism and potential clinical intervention
Jia, B., Xu, Y., & Zhu, X. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102711 · Cited by 31
Cavanagh, C., & Wong, T. P. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.01.003 · Cited by 29
“…ould slow down synaptic deficits by interrupting APP processing. myloid pathology and A production in APP mouse models can be ttenuated by blocking TNF signaling using either pharmacologial or genetic approaches (He et al., 2013, 2007; Shi et al., 2011) (but lso see (Chakrabarty et al., 2011)).”
BackgroundFerro, A., Qu, W., Lukowicz, A., Svedberg, D., Johnson, A., & Cvetanovic, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0200013 · Cited by 26
Botsakis, K., Mourtzi, T., Panagiotakopoulou, V., Vreka, M., Stathopoulos, G. T., Pediaditakis, I., Charalampopoulos, I., Gravanis, A., Delis, F., Antoniou, K., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.043 · Cited by 28
Apolipoprotein CI Knock-Out Mice Display Impaired Memory Functions
Berbée, J. F. P., Vanmierlo, T., Abildayeva, K., Blokland, A., Jansen, P. J., Lütjohann, D., Gautier, T., Sijbrands, E., Prickaerts, J., Hadfoune, M., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100576 · Cited by 25
Kurach, Ł., Kulczycka-Mamona, S., Kowalczyk, J., Skalicka‐Woźniak, K., Boguszewska‐Czubara, A., Sayed, N. S. E., Osmani, M., Iwaniak, K., & Budzyńska, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041779 · Cited by 28
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 30
“Furthermore, when the TNFR1 gene in transgenic AD mice was deleted, researchers observed an increase in Aβ generation, plaque burden and cognitive deficits [57].”
BackgroundTian, J., Zhai, Q., Zhao, Y., Chen, R., & Zhao, L. (2017) · Journal of Integrative Neuroscience · doi:10.3233/jin-170032 · Cited by 24
Zhuang, Y., Xu, H. C., Shinde, P. V., Warfsmann, J., Vasiļevska, J., Sundaram, B., Behnke, K., Huang, J., Hoell, J. I., Borkhardt, A., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318215 · Cited by 25
The Role of CNI-1493 in the Function of Primary Microglia with Respect to Amyloid-β
Bach, J.-P., Mengel, D., Wahle, T., Kautz, A., Balzer-Geldsetzer, M., Al-Abed, Y., Dodel, R., & Bacher, M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110179 · Cited by 23
Laske, C., Schmohl, M., Leyhe, T., Stransky, E., Maetzler, W., Berg, D., Fallgatter, A. J., Joos, T., & Dietzsch, J. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121558 · Cited by 22
Ortí-Casañ, N., Boerema, A. S., Köpke, K., Ebskamp, A., Keijser, J. N., Zhang, Y., Chen, T., Dolga, A. M., Broersen, K., Fischer, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36846-2 · Cited by 25
He, P., Li, P., Hua, Q., Liu, Y., Staufenbiel, M., Li, R., & Shen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058181 · Cited by 22
“Ab Enzyme-linked Immunosorbent Assay Enzyme-linked immunosorbent assay (ELISA) quantification was performed as described previously [34,35,36].”
BackgroundMethodInfluentialSelf-citationA cellular model of amyloid precursor protein processing and amyloid-β peptide production
Macias, M. P., Gonzales, A. M., Siniard, A. L., Walker, A. W., Corneveaux, J. J., Huentelman, M. J., Sabbagh, M. N., & Decourt, B. (2013) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.11.024 · Cited by 24
“APP, BACE1, and presenilin 1 (PSEN1) genes were selected as representing the substrate and enzymes, respectively, necessary for the amyloidogenic pathway, and TNFα, TNFR1, and TNFR2 genes were examined as mediators of inflammation that can influence Aβ production (He et al., 2007).”
BackgroundGuan, Z., Chen, Z., Fu, S., Dai, L., & Shen, Y. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00260 · Cited by 24
“Indeed, our previous studies have elucidated a critical role of the TNFα/TNFR signaling pathway in AD pathology through regulating BACE1 expression, which mediated by the NF-κB pathway (He et al., 2007; Jiang et al., 2014).”
BackgroundSelf-citationQuan, W., Luo, Q., Hao, W., Tomic, I., Furihata, T., Schulz‐Schaeffer, W., Menger, M. D., Fassbender, K. C., & Liu, Y. (2021) · Glia · doi:10.1002/glia.24007 · Cited by 20
“The expression of BACE1 in neurons is up-regulated by inflammatory acti- vation (He et al., 2007; Sastre et al., 2006).”
BackgroundPathway-specific TNF-mediated metaplasticity in hippocampal area CA1
Singh, A., Sateesh, S., Jones, O. D., & Abraham, W. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-05844-1 · Cited by 24
Mou, X., Pilozzi, A. R., Tailor, B. A., Yi, J., Cahill, C. M., Rogers, J. T., & Huang, X. (2020) · Biomedicines · doi:10.3390/biomedicines8030045 · Cited by 25
Core transcriptional regulatory circuits in prion diseases
Kim, T.-K., Lee, I. Y., Cho, J.-H., Canine, B. F., Keller, A. D., Price, N. D., Hwang, D., Carlson, G., & Hood, L. (2020) · Molecular Brain · doi:10.1186/s13041-020-0551-3 · Cited by 15
Lee, M. J., Wang, C., Carroll, M. J., Brubaker, D. K., Hyman, B. T., & Lauffenburger, D. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.727784 · Cited by 21
“…Fourgeaud et al., 2016; Keren-Shaul et al., 2017; Krasemann et al., 2017; Mathys et al., 2017; Butovsky and Weiner, 2018; Boza-Serrano et al., 2019; Herrera-Rivero et al., 2019; Kim et al., 2019; Puigdellívol et al., 2020; Tao et al., 2020; Burstyn-Cohen and Hochberg, 2021; Huang et al., 2021…”
BackgroundAdipose tissue as a therapeutic target for vascular damage in Alzheimer's disease
Bettinetti‐Luque, M., Trujillo‐Estrada, L., García‐Fuentes, E., Andreo‐Lopez, J., Sanchez-Varo, R. M., Garrido‐Sánchez, L., Mediavilla, A. G., López, M. G., García‐Caballero, M., Gutiérrez, A., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16243 · Cited by 24
“He et al., 2007).”
Death Receptors in the Selective Degeneration of Motoneurons in Amyotrophic Lateral Sclerosis
Aebischer, J., Bernard‐Marissal, N., Pettmann, B., & Raoul, C. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/746845 · Cited by 21
“While studies on death receptors have long been restricted to immune cells, the last decade has provided a strong body of evidence for their implication in neuronal death and hence neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS).”
BackgroundMetabolomic research on the role of interleukin-4 in Alzheimer’s disease
González‐Domínguez, R., García‐Barrera, T., Vitórica, J., & Gómez‐Ariza, J. L. (2015) · Metabolomics · doi:10.1007/s11306-015-0773-z · Cited by 18
“Thereby, common inflammatory targets investigated in these transgenic models are interleukins (Vom Berg et al. 2012), tumor necrosis factor (He et al. 2007) or nitric oxide synthase (Colton et al. 2006).”
Bid signal pathway components are identified in the temporal cortex with Parkinson disease
Jiang, H. F., He, P., Adler, C. H., Shill, H. A., Beach, T. G., Li, R., & Shen, Y. (2012) · Neurology · doi:10.1212/wnl.0b013e3182703f76 · Cited by 18
Self-citationNFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline
Delaby, C., Julian, A. G., Page, G., Ragot, S., Lehmann, S., & Paccalin, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89749-5 · Cited by 19
Therapeutic targets for Alzheimer's disease
Tarditi, A., Caricasole, A., & Terstappen, G. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902865614 · Cited by 18
Askari, S., Javadpour, P., Rashidi, F. S., Dargahi, L., Kashfi, K., & Ghasemi, R. (2022) · Life · doi:10.3390/life12091374 · Cited by 18
Herrmann, M., Anders, S., Straub, R. H., & Jenei‐Lanzl, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-27927-8 · Cited by 16
Kalovyrna, N., Apokotou, O., Boulekou, S., Paouri, E., Boutou, A., & Georgopoulos, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-65378-2 · Cited by 17
Jagadeesan, N., Roules, G. C., Chandrashekar, D. V., Yang, J., Kolluru, S., & Sumbria, R. K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05008-x · Cited by 21
Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients
Zhang, Z., Cui, J., Gao, F., Li, Y., Zhang, G., Liu, M., Yan, R., Shen, Y., & Li, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.11.018 · Cited by 16
“BACE1 enzymatic activity assays were performed as previous described with modifications (He et al., 2007; Shen et al., 2018).”
MethodSelf-citationPhilippens, I. H. C. H. M., & Langermans, J. A. M. (2021) · Vaccines · doi:10.3390/vaccines9040388 · Cited by 17
Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes
Duggan, M. R., Lu, A., Foster, T. C., Wimmer, M. E., & Parikh, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.834775 · Cited by 16
Microglial Modulation in Alzheimer’s Disease: Central Players in Neuroinflammation and Pathogenesis
Hussain, M. S., Khan, Y., Fatima, R., Maqbool, M., Ramalingam, P. S., Khan, M. G., & Bisht, A. S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050364292250113063513 · Cited by 18
Gao, H., Bigalke, J. A., Jiang, E., Fan, Y., Chen, B., Chen, Q., & Shan, Z. J. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01056-9 · Cited by 16
Giudici, K. V., Barreto, P. D. S., Guyonnet, S., Morley, J. E., Nguyen, A. D., Aggarwal, G., Parini, A., Li, Y., Bateman, R. J., Vellas, B. J., et al. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac244 · Cited by 14
Yin, T., Ramon, A., Greenig, M., Sormanni, P., & D'adamio, L. (2025) · mAbs · doi:10.1080/19420862.2025.2498164 · Cited by 15
“48 Furthermore, TNFα regulates synaptic receptor trafficking by promoting AMPA receptor export and GABA receptor import.”
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 15
He, P., Xin, W., Schulz, P., & Sierks, M. R. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1597-z · Cited by 14
Self-citationCalvillo, M., Díaz, A., Limón, I. D., Mayoral, M. Á., Chánez‐Cárdenas, M. E., Zenteno, E., Montaño, L. F., Guevara, J., & Espinosa, B. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.06.002 · Cited by 15
Oh, S. L., Zhou, M., Chin, E., Amarnath, G., Cheah, C. H., Ng, K. P., Kandiah, N., Goh, E. L. K., & Chiam, K. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.875895 · Cited by 13
“Numerous studies have described the elevation of TNF-α in AD patients (46, 47) and the intervention of this pathway has been shown to alleviate brain pathology in rodent models (48).”
BackgroundLiu, W., Li, W., Liu, Z., Li, Y., Wang, X., Guo, M., Wang, S., Wang, S., Li, Y., & Jia, J. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01463-2 · Cited by 11
Acute Kidney Injury, Systemic Inflammation, and Long-Term Cognitive Function
Bhatraju, P. K., Zelnick, L. R., Stanaway, I. B., Ikizler, T. A., Menez, S. P., Chinchilli, V. M., Coca, S. G., Kaufman, J. S., Kimmel, P. L., Parikh, C. R., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000473 · Cited by 12
“30 In clinical studies, plasma sTNFR-1 concentrations have been shown to be elevated after AKI, and elevated concentrations of plasma sTNFR-1 have been associated with worse long-term outcomes, such as heart failure and death.”
TNF and Leptin Tell Essentially the Same Story in Alzheimer's Disease
Clark, I. A., Alleva, L. M., & Vissel, B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110266 · Cited by 12
He, P., Schulz, P., & Sierks, M. R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015327 · Cited by 11
“Immunostaining was performed as described previously (22, 34, 57).”
MethodSelf-citationManap, A. S. A., Madhavan, P., Vijayabalan, S., Chia, A. Y. Y., & Fukui, K. (2020) · PeerJ · doi:10.7717/peerj.10003 · Cited by 12
Huang, Z. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221042 · Cited by 14
Maglione, A., do Nascimento, B. P. P., Ribeiro, M. O., de Souza, T. J. L., da Silva, R. E. C., Sato, M. A., Penatti, C. A. A., Britto, L. R., de Souza, J. S., Maciel, R. M. B., et al. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01055-9 · Cited by 12
Viable mouse gene ablations that robustly alter brain Aβ levels are rare
Toyn, J. H., Lin, X.-A., Thompson, M. W., Guss, V. L., Meredith, J. E., Sankaranarayanan, S., Barrezueta, N. X., Corradi, J., Majumdar, A., Small, D. L., et al. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-143 · Cited by 13
“In brief, BACE1 activity can be regulated through a variety of molecular targets involved in cytokine signaling [11,12], hypoxia [13,14], oxidative stress [15], energy deprivation [16], intracellular trafficking and maturation [17-19], and glycosylphosphatidylinositol (GPI) anchor metabolism [20-22].”
BackgroundCurcumin and Inflammatory Brain Diseases
Shehzad, A., Islam, S. U., & Lee, Y. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815461-8.00024-4 · Cited by 16
Guo, S., Zhang, Y., Wei, C., Shi, L., & Feng, Y. (2019) · The Anatomical Record · doi:10.1002/ar.24238 · Cited by 11
“Deletion of the TNF receptor 1 (TNFR1) gene has been shown to reduce amyloid-beta (Aβ) production and improve behavior inmice with AD (He et al., 2007; Jiang et al., 2011).”
BackgroundPPAR Co-Activator-1 (PGC-1) Reduces Amyloid- Generation Through aP PAR-Dependent Mechanism
Katsouri, L., Parr, C., Bogdanović, N., Willem, M., & Sastre, M. (2011) · Cited by 11
Tian, Y., Fopiano, K. A., Buncha, V., Lang, L., Suggs, H. A., Wang, R., Rudic, R. D., Filosa, J. A., & Bagi, Z. A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1125932 · Cited by 11
Metadata
- Authors
- He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y.
- Affiliations
- Banner Sun Health Research Institute (US)
- 1Haldeman Laboratory of Molecular and Cellular Neurobiology
- Brigham and Women's Hospital (US)
- Novartis (Switzerland) (CH)
- Corresponding author
- Shen, Yong
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2007-08-27
- Volume
- 178
- Issue
- 5
- Pages
- 829-841
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2064547
- OpenAlex
- W2096277075
- Cited by
- 390
- References
- 76
- Citations by year
- 2026: 16 · 2025: 12 · 2024: 27 · 2023: 11 · 2022: 18 · 2021: 21 · 2020: 23 · 2019: 21 · 2018: 21 · 2017: 17 · 2016: 15 · 2015: 30 · 2014: 35 · 2013: 24 · 2012: 18
- FWCI
- 11.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG025888, AG025888)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tumor necrosis factor receptor 1, Alzheimer's disease, amyloid-beta production, amyloid plaques, APP processing, beta-secretase 1, BACE1, NF-κB signaling, APP23 transgenic mice, learning and memory impairment, neurodegeneration, death receptor signaling
- MeSH terms
- Alzheimer Disease, Animals, Behavior, Animal, Disease Models, Animal, Gene Expression Regulation, Humans, Insulysin, Learning, Memory Disorders, Mice, Transgenic, Neurons, Promoter Regions, Genetic, Tumor Necrosis Factor-alpha, Neprilysin, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, NF-kappa B, Cerebral Amyloid Angiopathy, Gene Deletion, Microglia, Mice, Knockout, Receptors, Tumor Necrosis Factor, Type I, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.